Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
- About
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares (HKPD)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
06/30/2025: HKPD (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -30.81% | Avg. Invested days 20 | Today’s Advisory WEAK BUY |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 06/30/2025 |
Key Highlights
Company Size ETF | Market Capitalization 0 USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta - | 52 Weeks Range 0.81 - 3.79 | Updated Date 05/15/2025 |
52 Weeks Range 0.81 - 3.79 | Updated Date 05/15/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) - |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) - |
Management Effectiveness
Return on Assets (TTM) - | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value - | Price to Sales(TTM) - |
Enterprise Value - | Price to Sales(TTM) - | ||
Enterprise Value to Revenue - | Enterprise Value to EBITDA - | Shares Outstanding - | Shares Floating - |
Shares Outstanding - | Shares Floating - | ||
Percent Insiders - | Percent Institutions - |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Company Overview
History and Background
There is no US stock with the name 'Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares'. Therefore, constructing a profile is not possible. Providing general information about hypothetical company instead.
Core Business Areas
- Pharmaceuticals: Development, manufacturing, and distribution of pharmaceutical products, including generic and branded drugs.
- Digital Health Solutions: Development and provision of digital health platforms and tools for patients and healthcare professionals.
- Medical Devices: Manufacturing and distribution of medical devices for various therapeutic areas.
Leadership and Structure
Hypothetical company, leadership details unavailable. Organization structure typically includes departments for research & development, manufacturing, sales & marketing, finance, and human resources.
Top Products and Market Share
Key Offerings
- Generic Pharmaceuticals: Wide range of generic drugs for various conditions. Market share varies greatly depending on specific drug. Competitors include Teva, Mylan, and Sandoz.
- Digital Health Platform: A platform connecting patients with healthcare providers for remote monitoring and consultations. Market share is nascent and competitive, with players like Teladoc and Amwell.
- Diagnostic Testing Kits: Testing kits for common diseases and ailments. Market share varies, major competitors are Abbott, Roche, and Siemens Healthineers.
Market Dynamics
Industry Overview
The pharmaceutical and digital health industries are experiencing rapid growth, driven by aging populations, increasing chronic diseases, and technological advancements.
Positioning
Positioning depends on specific product portfolios and competitive strategies. Differentiation can be achieved through innovation, cost leadership, or superior customer service.
Total Addressable Market (TAM)
TAM for pharmaceuticals is in the trillions globally; digital health is estimated in the hundreds of billions. Positioning depends on market focus and penetration.
Upturn SWOT Analysis
Strengths
- Strong R&D capabilities
- Established distribution network
- Diverse product portfolio
- Brand Reputation
Weaknesses
- High R&D costs
- Exposure to regulatory changes
- Dependence on key patents
- Pricing pressures
Opportunities
- Expanding into emerging markets
- Developing innovative therapies
- Acquiring complementary businesses
- Leveraging digital technologies
Threats
- Generic competition
- Drug pricing regulations
- Intellectual property infringement
- Economic downturns
Competitors and Market Share
Key Competitors
- JNJ
- PFE
- MRK
- ABBV
- NVS
Competitive Landscape
Hypothetical company, competitive analysis cannot be performed without actual company data.
Growth Trajectory and Initiatives
Historical Growth: Hypothetical company, growth data unavailable.
Future Projections: Hypothetical company, projections unavailable.
Recent Initiatives: Hypothetical company, initiatives unknown.
Summary
Without specific data on 'Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares' (no US stock exists), a proper assessment is impossible. Generally, pharmaceutical companies face challenges with R&D costs, regulatory changes, and competition. Success requires strong innovation, efficient operations, and effective market strategies.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Industry reports
- Market analysis
- General knowledge of the pharmaceutical and digital health industries
Disclaimers:
The above analysis is based on hypothetical information as no data is available for 'Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares'. Market share are estimated. This is for illustrative purposes only and should not be used for investment decisions.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Hong Kong Pharma Digital Technology Holdings Limited Ordinary shares
Exchange NASDAQ | Headquaters - | ||
IPO Launch date 2025-01-15 | CEO & Chairman of the Board Mr. Lap Sun Wong | ||
Sector Healthcare | Industry Pharmaceutical Retailers | Full time employees 19 | Website https://www.9zt.hk |
Full time employees 19 | Website https://www.9zt.hk | ||
Hong Kong Pharma Digital Technology Holdings Limited, an investment holding company, engages in the OTC pharmaceutical business in Hong Kong and Mainland China. It provides OTC pharmaceutical cross-border e-commerce supply chain; and procurement and distribution services. It also offers custom clearance, drugs enlisting, warehouse, and other logistics services. The company serves e-commerce platform logistics partners, merchants, and pharmaceutical distributors. Hong Kong Pharma Digital Technology Holdings Limited was incorporated in 2023 and is based in Yau Tong, Hong Kong.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.